Patents by Inventor David Taiwai Wong

David Taiwai Wong has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Inhibitor of monoamine uptake
    Patent number: 7384983
    Abstract: The present invention provides compounds and methods for the inhibition of monoamine uptake in mammals.
    Type: Grant
    Filed: May 9, 2005
    Date of Patent: June 10, 2008
    Assignee: Eli Lilly and Company
    Inventors: Edward Louis Mattiuz, John-Michael Sauer, William Joe Wheeler, David Taiwai Wong
  • Inhibitor of monoamine uptake
    Publication number: 20040082666
    Abstract: The present invention provides compounds and methods for the inhibition of monoamine uptake in mammals.
    Type: Application
    Filed: August 21, 2003
    Publication date: April 29, 2004
    Inventors: Edward Louis Mattiuz, John-Michael Sauer, William Joe Wheeler, David Taiwai Wong
  • Piperidine derivatives having effects on serotonin related systems
    Patent number: 6436964
    Abstract: The present invention provides the compounds of the following formula: Wherein the variables are as defined in the specification and a method for inhibiting the reuptake of seretonin, antagonizing the 5-HT1A receptor and antagonizing the 5-HT2A receptor which comprises administering to a subject in need of such treatment an effective amount of the compound of above formula.
    Type: Grant
    Filed: November 28, 2000
    Date of Patent: August 20, 2002
    Assignee: Eli Lilly and Company
    Inventors: Larry Wayne Hertel, Daniel Timothy Kohlman, Sidney Xi Liang, David Taiwai Wong, Yao-Chang Xu
  • Arylpiperazines as serotonin reuptake inhibitors and 5-HT1D&agr; antagonists
    Patent number: 6342498
    Abstract: Anylpiperazines of formula (1) useful as serotonin reuptake inhibitors and 5-HT1D&agr; receptor antagonists are disclosed herein: wherein R1 and R2 are each independently hydrogen, halo, —(C1-C6)alkyl or —(C1-C6)alkoxy; R3 is hydrogen or —(C1-C6)alkyl; Y is —CO— or —CH2—; Z is —NH—, —N(COR)— or —CH2— where R is —(C1-C6)alkyl or —(C3-C8)cycloalkyl; represents a double or single bond; n and m are an each independently integer from 1 to 3, both inclusive; or a pharmaceutically acceptable salt thereof.
    Type: Grant
    Filed: March 31, 2000
    Date of Patent: January 29, 2002
    Assignee: Eli Lilly and Company
    Inventors: Clint Duane Walker, David Taiwai Wong, Yao-Chang Xu
  • Potentiation of drug response
    Patent number: 6169105
    Abstract: The power of citalopram, fluvoxamine and paroxetine to increase the availability of sarotonin, norepinephrine and dopamine, particularly serotonin, is augmented by administration in combination with a drug which is a serotonin 1A receptor antagonist.
    Type: Grant
    Filed: November 25, 1996
    Date of Patent: January 2, 2001
    Assignee: Eli Lilly and Company
    Inventors: David Taiwai Wong, Juan Ignacio Oguiza
  • Thienobenzodiazepine compounds
    Patent number: 6034078
    Abstract: Pharmaceutical compounds of the formula ##STR1## in which R.sup.1 is hydrogen or halo, and R.sup.2 is C.sub.1-10 alkyl, C.sub.2-10 alkenyl, C.sub.2-10 alkynyl, C.sub.3-6 cycloalkyl optionally substituted by 1 to 3 C.sub.1-4 alkyl groups, C.sub.3-6 cycloalkyl-C.sub.1-4 alkyl in which the cycloalkyl group is optionally substituted by 1 to 3 C.sub.1-4 alkyl groups, or optionally substituted phenyl-C.sub.1-4 alkyl; or a salt thereof. Such compounds are useful for treating a disorder of the central nervous system which is associated with the modulation of a 5-HT.sub.3 receptor.
    Type: Grant
    Filed: July 1, 1997
    Date of Patent: March 7, 2000
    Assignees: Eli Lilly and Company Limited, Eli Lilly and Company
    Inventors: John Fairhurst, Terrence Michael Hotten, David Edward Tupper, David Taiwai Wong